Liposomal Irinotecan Shows a Larger Therapeutic Index than Non-liposomal Irinotecan in Patient-Derived Xenograft Models of Pancreatic Cancer

Autor: Sandrine Barbier, Benjamin Beaufils, Ricardo de Miguel, Melissa Reyre, Yannick Le Meitour, Andreanne Lortie, Marc Hillairet de Boisferon, Sophie Chaumeron, Anne Espirito, Lina Fossati, Pauline Lagarde, Stephan Klinz, Arunthathi Thiagalingam, Stéphane Lezmi, Florence Meyer-Losic

Publikováno v: Oncology and Therapy, Vol 11, Iss 1, Pp 111-128 (2023)

Abstract Introduction Liposomal irinotecan promotes controlled sustained release of irinotecan (CPT-11), therefore, we hypothesize that the therapeutic index (quantitative measurement of the relative efficacy/safety ratio of a drug) will be higher fo

Externí odkaz: https://doaj.org/article/be2e3c3c269d460ab70f6f7799bd0e5d

Abstract PO053: Efficacy of cabozantinib after immune checkpoint inhibition in a syngeneic tumor model

Autor: Florence Meyer-Losic, Sophie Chaumeron, Sylvie Rolland, Stephan G Klinz, Marc Hillairet de Boisferon

Publikováno v: Cancer Immunology Research. 9:PO053-PO053

Background: The tyrosine kinase inhibitor cabozantinib showed clinical activity in 1L RCC as well as RCC and HCC in 2L after treatment with anti-angiogenic therapy where it prolonged survival. Immune checkpoint inhibition (ICI) is rapidly becoming a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fd78ec2bba5cbaa03d50b75f382aada8
https://doi.org/10.1158/2326-6074.tumimm20-po053

Anticancer Activity of BIM-46174, a New Inhibitor of the Heterotrimeric Gα/Gβγ Protein Complex

Autor: Gregoire Prevost, Pierre Roubert, Daniel W. Zaharevitz, Marie Odile Lonchampt, Samir Attoub, Sophie Chaumeron, Mike Alley, Erik Bruyneel, Hélène Coulomb, Ann Savola, Philip G. Kasprzyk, Susan Holbeck, John Wright, Quang-Dé Nguyen, Patricia Forgez, Christian Gespach, Marie C. Brezak, Mark Bracke, Eric Ferrandis, Marion Huchet, Danièle Demarquay

Publikováno v: Cancer Research. 66:9227-9234

A large number of hormones and local agonists activating guanine-binding protein-coupled receptors (GPCR) play a major role in cancer progression. Here, we characterize the new imidazo-pyrazine derivative BIM-46174, which acts as a selective inhibito

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7e35e09855de720491c38a3f5fd371a5
https://doi.org/10.1158/0008-5472.can-05-4205

Pharmacologic inhibition of CDC25 phosphatases impairs interphase microtubule dynamics and mitotic spindle assembly

Autor: Gregoire Prevost, Rose Boutros, Bernard Ducommun, Martine Cazales, Sophie Chaumeron, Marie-Christine Brezak

Publikováno v: Molecular Cancer Therapeutics
Molecular Cancer Therapeutics, American Association for Cancer Research, 2007, 6 (1), pp.318-325
Molecular Cancer Therapeutics, American Association for Cancer Research, 2007, 6 (1), pp.318-25. ⟨10.1158/1535-7163.MCT-06-0299⟩

The CDC25 cell cycle regulators are promising targets for new pharmacologic approaches in cancer therapy. Inhibitory compounds such as BN82685 have proven to be effective in specifically targeting CDC25 in cultured cells and in inhibiting tumor cell

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0e1bedf4e2be650e583b456e4613334
https://pubmed.ncbi.nlm.nih.gov/17237290